Event
AI Drug Discovery & Development Summit 2026
Date:27–29 October 2026
Location: Boston, MA, USA
Sarah Bernard
BD Senior Director – North America
Artificial intelligence is opening new possibilities in drug discovery, from identifying promising therapeutic targets to accelerating compound design and optimization. But turning computational predictions into meaningful scientific progress requires reliable experimental evidence.
The AI Drug Discovery & Development Summit 2026 will bring together pharmaceutical and biotechnology professionals to explore how AI, machine learning, and advanced technologies are transforming drug discovery and development.
Sarah Bernard, Senior Director East Coast BD & Sales at Axxam, will attend the summit in Boston to connect with industry experts and exchange perspectives on the evolving landscape of AI-driven drug discovery.
Bridging AI Predictions and Experimental Drug Discovery
AI-driven approaches can help researchers navigate complex biological datasets, prioritize targets, and identify promising compounds. However, experimental validation remains essential to assess biological activity, characterize mechanisms of action, and guide further optimization.
At Axxam, we provide target validation, assay development, high-throughput screening, and compound profiling capabilities to support the experimental investigation of therapeutic hypotheses and promising molecules.
By generating robust biological data, our technologies can complement computational drug discovery strategies and help researchers make informed decisions throughout early discovery.
Turning Data into Drug Discovery Decisions
As computational methods continue to evolve, connecting predictive models with relevant biological systems becomes increasingly important.
From disease-relevant cellular models to advanced phenotypic screening and functional assays, Axxam supports the generation of experimental insights needed to evaluate complex biological responses and characterize compound activity.
Our integrated drug discovery capabilities help bridge the gap between promising scientific hypotheses and experimentally validated findings.
Meet Axxam in Boston
Are you attending the AI Drug Discovery & Development Summit 2026?
Connect with Sarah Bernard to discuss how experimental screening, biological validation, and integrated discovery capabilities can complement your drug discovery strategy.